Bristol-Myers Squibb Applies to Sell New AIDS Drug in Europe
May 30, 2002
Bristol-Myers Squibb said Wednesday it has applied to the European equivalent of the US Food and Drug Administration for clearance to market and sell Atazanavir, a drug currently in development for the treatment of HIV/AIDS. The drug is a viral protease inhibitor that has shown potential for once-daily use, Bristol scientists said. Trials have included more than 1,500 patients whose conditions run the spectrum of HIV infection.Adapted from:
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.